HyperArc Registry Study

The HyperArc registry is designed to collect data from which the efficacy of the HyperArc procedure can be assessed and compared to alternative treatments.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Brain Metastases Brain Diseases Brain Neoplasms CNS Disorder, Intracranial CNS Neoplasm Central Nervous System Diseases Central Nervous System Neoplasms Neoplasms Neoplasms by Site Nervous System Diseases Nervous System Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Icon Cancer Centre Canberra, Bruce, Australian Capital Territory, Australia

About this study

A significant percentage of newly diagnosed cancer patients will develop brain metastases. For many of these patients, stereotactic radiosurgery (SRS) is recommended as a primary treatment option. Concerns about complexity, patient safety, cost, and human resources can make SRS challenging. HyperArc radiotherapy addresses these challenges by introducing key technology and workflow elements to streamline multi-leaf collimator-based, non-coplanar SRS. HyperArc is designed to deliver SRS treatments from the TrueBeam linear accelerator platform. The HyperArc registry is designed to collect data from which the efficacy of the HyperArc procedure can be assessed and compared to alternative treatments.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Received or scheduled to receive treatment using the HyperArc treatment method
Age of legal adult according to local law
Signed informed consent form, or, informed consent waived by the local ethics board/institutional review board

Exclusion criteria

None, apart from not meeting Inclusion Criteria

Treatment and study plan

Stereotactic Radiosurgery

Radiation

HyperArc is a radiotherapy treatment with a structured workflow to plan and deliver stereotactic radiosurgery (SRS).

Other names: HyperArc SRS

Primary outcomes

Survival

Time frame: follow until death, on average approximately 2 years

Survival

Secondary outcomes

Local tumor control

Time frame: follow until death, on average approximately 2 years

Response of treated tumors
HyperArc Patterns of Care

Time frame: Limited to course of treatment: up to 4 weeks

Dosimetry information for clinically delivered HyperArc treatments

Sponsors and collaborators

Lead sponsor

Varian, a Siemens Healthineers Company

Industry

Registry information

Important dates

Study start: 2022
Primary completion: 2025
Study completion: 2025
First posted: Mar 8, 2022
Registry last updated: Sep 24, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed